<DOC>
	<DOCNO>NCT01756703</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamics , safety , tolerability pharmacokinetics MT-3995 Type II Diabetic Nephropathy Subjects Albuminuria</brief_summary>
	<brief_title>A Study Evaluate Pharmacodynamics , Safety , Tolerability Pharmacokinetics MT-3995 Type II Diabetic Nephropathy Subjects With Albuminuria</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>Subjects Type II diabetic nephropathy , treat angiotensin convert enzymeinhibitor ( ACEI ) angiotensin II receptor blocker ( ARB ) Glycosylated haemoglobin ( HbA1c ) ≤10.5 % An estimate glomerular filtration rate ( eGFR ) ≥60 mL/min/1.73m^2 Subject albuminuria History Type I diabetes , pancreas βcell transplantation , diabetes secondary pancreatitis pancreatectomy Serum potassium level &lt; 3.5 &gt; 5.0 mmol/L Subjects acute kidney injury ( AKI ) within 3 month prior baseline undergone renal dialysis time prior randomisation Subjects history renal transplant Subjects clinically significant hypotension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>